Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

The effect of Abl kinases,or Ponatinib challenging on breast cancer cells' global transcriptome

ABSTRACT: To gain insight into the signaling pathway(s) required for ABL1/ABL2-kinase activity or effected by Ponatinib treatment, we evaluated the consequences of single or double inactivation of ABL1/ABL2 cells, or Ponatinib treated cells on the transcriptome of breast cancer cells. To examine the consequences of depleting the ABL kinases, or Ponatinib treatment on the transcriptome of lung metastatic breast cancer cells we employed next generation sequencing (RNAseq) analysis. We found that 321 genes were significantly differently expressed in Ponatinib treated LM2 cells, and 73 genes were differently expressed in double inactivation of ABL1/ABL2 LM2 cells. However, only about 3.4 percent of Ponatinib affected genes can also be changed by ABL knocking down.

ORGANISM(S): Homo sapiens

PROVIDER: GSE95079 | GEO | 2018/03/01

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Similar Datasets

The effect of knockdown Abl kinases on breast cancer cells' global transcriptome

Project description:To gain insight into the signaling pathway(s) required for ABL1/ABL2-dependent bone metastasis, we evaluated the consequences of single or double inactivation of ABL1 and ABL2 on the transcriptome of breast cancer cells. Double ABL1/ABL2 knockdown was required to decrease the levels of p-CrKL by more than 90%, indicative of inactivation of the endogenous ABL kinases. To examine the consequences of depleting the ABL kinases on the transcriptome of metastatic breast cancer cells we employed next generation sequencing (RNAseq) analysis. We found that 180 genes were significantly down-regulated and 40 genes were significantly up-regulated in ABL1/ABL2 knockdown cells. Four samples were analyzed control, Abl single knockdown, Arg single knockdown, Abl/Arg double knockdown. Experiments were performed in triplicate.

2016-03-02 | E-GEOD-69125 | biostudies-arrayexpress

The effect of knockdown Abl kinases on breast cancer cells' global transcriptome

2016-03-02 | GSE69125 | GEO

Abl subtrates using tyrosine phosphoproteomics

Project description:In this study, we have prepared a mouse embryonic fibrobalst (MEF) cell line stably expressing R367A mutant human Abl in which the native mouse Abl1 and Abl2 were genetically deleted. We have used these R367A mutant Abl cells in combination with mass spectrometry to identify phosphorylation targets of Abl. Below, we describe these findings and their potential biological significance.

2018-03-16 | PXD007118 | Pride

The role of ABL kinases in medulloblastoma

Project description:Medulloblastoma is the most common malignant pediatric brain tumor, and leptomeningeal dissemination (LMD) of medulloblastoma portends a poorer prognosis at diagnosis and is incurable at recurrence. The biological mechanisms underlying LMD in medulloblastoma are largely unclear. The Abelson (ABL) family of non-receptor tyrosine kinases has been implicated in cancer cell migration, invasion, adhesion, and chemotherapy resistance, and these kinases are upstream mediators of the oncogene c-MYC in fibroblasts. However, their role in medulloblastoma has not yet been explored. Therefore, the purpose of this work is to elucidate the role of the ABL kinases, ABL1 and ABL2, in medulloblastoma LMD. We show here that ABL1/2 mRNA is highly expressed in human medulloblastoma tumor samples and cell lines and that pharmacologic inhibition of ABL kinases results in medulloblastoma cell death. Knockdown of the ABL kinase genes ABL1 and ABL2 results in decreased adhesion to the extracellular matrix protein, vitronectin, and decreased medulloblastoma proliferation in a mouse model of medulloblastoma LMD (resulting in decreased tumor burden with subsequent increased overall survival. Further, both pharmacologic inhibition of ABL1/2 and ABL1/2 knockdown resulted in decreased c-myc expression, revealing a putative signaling pathway. In summary, this work highlights the potential role of ABL kinases in medulloblastoma LMD via c-myc expression.

2023-10-04 | GSE224691 | GEO

Signalling Inhibition by Ponatinib Disrupts Productive Alternative Lengthening of Telomeres (ALT)

Project description:Alternative lengthening of telomeres (ALT) supports telomere maintenance and replicative immortality in around 10-15% of cancers, thus representing a compelling target for therapy.To identify anti-cancer drugs that can be repurposed as ALT-centered therapies, we performed for a compound library screen on isogenic cell lines that rely either on telomerase or ALT mechanisms. We validated candidates on a panel of ALT- vs. telomerase-positive sarcoma cells and assessed levels of extrachromosomal telomeric C-circles after drug treatment, as a bona fide marker of ALT activity. We identified a receptor tyrosine kinase inhibitor ponatinib that deregulated ALT mechanisms, increased telomeric replicative stress and induced telomeric dysfunction in ALT cells. Using a model of ALT sarcoma xenografts, we found that ponatinib targeted ALT-positive cells and mitigated telomere elongation in these tumors. To identify the mode of action of ponatinib on ALT, we performed RNA-sequencing and quantitative proteomic and phosphoproteomic analyses, and shortlisted candidates to test the effect of their loss on telomeric C-circle levels. We identified an ABL1-JNK-JUN signalling circuit to be inhibited by ponatinib and to have a role in suppressing extrachromosomal telomeric C-circle formation. Furthermore, transcriptome and interactome analyses of JUN suggested a role of JUN in DNA damage repair pathways, independently of its capacity as a transcription factor. These results were corroborated by new synergistic drug interactions between ponatinib and either DNA synthesis or repair inhibitors such as triciribine and KU-60019, respectively. Overall, we identified a novel signalling pathway impacting ALT which can be targeted by a clinically approved kinase inhibitor.

2022-03-14 | PXD032188 | Pride

Signalling Inhibition by Ponatinib Disrupts Productive Alternative Lengthening of Telomeres (ALT)

2023-02-20 | PXD037501 | Pride

mRNA expression microarray of treatment naive vs. ponatinib-resistant DMS114 lung cancer cells

Project description:Transcriptional changes in consequence of in vitro resistance development of FGFR1-driven DMS114 lung cancer cells against the multikinase inhibitor ponatinib

2020-02-12 | E-MTAB-8773 | biostudies-arrayexpress

Bulk RNA-seq was performed on murine Lin-Sca+Kit+ (LSK) bone marrow cells from a transgenic SCLtTA/BCR-ABL (DTG) mouse BM cells (CD45.2) in which BCR-ABL1 was expressed or not expressed

Project description:Bulk RNA-seq was performed on murine Lin-Sca+Kit+ bone marrow cells from a transgenic SCLtTA/BCR-ABL (DTG) mouse BM cells (CD45.2) to understand the molecular consequences of BCR-ABL1 expression on the global mRNA programme of these cells.

2023-12-19 | GSE242036 | GEO

Signalling inhibition by ponatinib disrupts alternative lengthening of telomeres (ALT)

Project description:Analyses of gene expression changes in cells treated with ponatinib (experiment 1), and in cells either lacking JUN or overexpressing JUN (experiment 2).

2023-01-30 | GSE190438 | GEO

The effect of Abl kinases on non-small cell carcinoma global transcriptome

Project description:To gain insight into the signaling pathway(s) required for ABL1/ABL2-dependent non-small cell carcinoma cells metastasis

2017-01-28 | GSE77422 | GEO